Complete Remission After Treatment With Biologics for Nasal Polyps

Last updated: November 25, 2025
Sponsor: Rigshospitalet, Denmark
Overall Status: Active - Recruiting

Phase

4

Condition

Rhinitis, Allergic, Perennial

Nasal Obstruction

Polyps

Treatment

DUPIXENT®

Mepo discontinuation

NUCALA®

Clinical Study ID

NCT07268313
Rigshospitalet-ENT-1
  • Ages > 18
  • All Genders

Study Summary

In this RCT the investigators randomize patients who are treated with biologic treatment (Nucala or Dupixent) due to nasal polyps and have controlled disease within the last year to either stop treatment og continue as a control group.

Eligibility Criteria

Inclusion

Inclusion Criteria:

5.1 Inclusion criteria (all must be fulfilled)

Inclusion criteria:

At the time when the patient started biological treatment, they must have fulfilled the EPOS criteria for initiation of biologic treatment (REF EPOS):

  • Fulfil the criteria for CRSwNP

  • Presence of bilateral polyps in a patient

  • Had ESS (sinus surgery) (exceptional circumstances excluded)

  • Fulfil at least three of the following five criteria Evidence of type 2 inflammationNeed for (and treated with) systemic corticosteroids or contraindication to theseSNOT-22 score of 40 or above Significant loss of smell Asthma needing regularinhaled corticosteroids

To enter this study, the patient must be:

  • Above 18 years of age

  • Currently be in treatment with either Dupilumab (300 mg) or Mepolizumab (100 mg)with treatment every fourth week. This treatment should have been stable/unchangedfor at least three months.

  • Within the latest year, the patient must at all times have scored all the belowsymptoms of CRS five or below on a VAS scale from 0 - 10 - Doing this, it isaccording to the EPOS defined as controlled disease. The items are: nasal blockage,rhinorrhea/postnasal drip, facial pain/pressure, smell, sleep disturbance orfatigue) Please view appendix 2.

  • Within the latest year the nasal endoscopy cannot have showed polyp score of morethan 1+1 out of 4+4, further, no thick secretions or general oedema must have beenpresent.

  • Within the latest year the patient is not allowed to have had ESS or rescuetreatment for their CRSwNP (antibiotics or systemic steroids)

  • The patient must be able to understand Danish and able to sign an informed content.

Exclusion

Exclusion Criteria:

  • In the twelve months of remission the patient is not allowed to have had AECRS (acute exacerbation of chronic rhinosinusitis). A common cold is allowed.

  • Polyp removal in the out-patient clinic may not have been performed within the last 3 months.

  • In the twelve months of remission the patient cannot at any time have scored higherthan 1.2 on the ACQ questionnaire, meaning that the patient does not haveuncontrolled asthma (Appendix 3).

  • Patients who, because of language barriers, are not able to understand writteninformation and, thus, are not able to answer questionnaires.

  • Patients who currently receive biologics for any other disease (asthma not included)

  • Patients who are not able to give informed consent (i.e., patients who arepermanently incapable)

  • Patients who are not eligible because of the investigator's judgement

  • Patients who experience pregnancy during the study will be excluded after anunscheduled visit (LOCF) - active IVF treatment. (Please look belove)

  • Patients who have or recently have had illness, such as cancer that or its treatmentis expected to significantly affect morbidity and/or quality of life in the next twoyears

  • Unwillingness to follow the study procedure

  • Hypersensitivity to any of either Dupilumab or Mepolizumab.

Study Design

Total Participants: 66
Treatment Group(s): 4
Primary Treatment: DUPIXENT®
Phase: 4
Study Start date:
April 03, 2025
Estimated Completion Date:
June 01, 2027

Study Description

11 Protocol Synopsis 11.1. EU trial number and full trial title: 2024- 5196285-25-00 English title: Complete remission study Subtitle: Discontinuation of Mepolizumab or Dupilumab after at least 12 months without symptoms in patients with severe Chronic rhinosinusitis with polyps - a National Danish RCT study.

11.2. Rationale Specify background and hypothesis of the trial. The Danish Medicines Council has decided that well-controlled patients with nasal polyps should try to cease the medication after two years of treatment with biologics (Mepolizumab or Dupilumab). The investigators find this better to do in a RCT. Based on the experience from asthma patients this could be done in some patients without the symptoms reoccur.

11.3. Objective Specify the main and secondary objectives of the trial. The main objective is to find the percentage of patients in complete remission (no or few symptoms) who can cease the biologic treatment and keep being in remission. The secondary objective is to observe if one or the other drug is more likely to give this result.

11.4. & 11.5 Main and secondary trial endpoints: The main endpoint is to monitor the percentage of patients who do not have recurrence of their sino-nasal symptoms when they cease medicine. This is evaluated at baseline and after 12,26,38,52 weeks, however, the patients can contact the investigators at any time if symptoms reoccur. A control group is included and it is assumed that patients kept on treatment will keep being in complete remission. No adverse effects are expected, thus no new medication is started.

11.6. Trial design: Non-blinded, prospective RCT. Half the included patients will keep their treatment unchanged (control-group) the other half will stop the biological treatment (everything else unchanged). Every individual participant will have a 52-week follow-up period. If a participant in the trial group gets symptoms and feel partly uncontrolled they will start treatment again with same drug, dose and interval as before the cease.

11.7. Trial population: Patients over 18 years of age, who have been on hospital administrated biologic treatment for at least 1½ year and have been in remission for at least a year.

11.8. Interventions: The participants are randomized into two groups: one group (33 patients) will be the control group with no change in their treatment, the other group (33 patients) will cease treatment.

11.9. Ethical considerations. The investigators have very few ethical concerns by conducting this study. It is highly unlikely that any side effects will occur, thus there is no suspicion that reducing dose of biologics gives risks of side effects.

Further, none of the examinations or questionnaires are add-on to the examinations that the patients must go through when being in biologic treatment.

The investigators only concern is that some patients will experience recurrence of sino-nasal and/or asthma symptoms when stopping the biologic medicine. However, there is a plan for handling this safely. Lastly, it should also be kept in mind that the Danish medicines council recommends trying to stop the treatment, thus the investigators find it better to do this under RCT conditions.

Connect with a study center

  • Rigshospitalet

    Copenhagen 2618425, Region H 2100
    Denmark

    Active - Recruiting

  • Nordsjællands hospital

    Hillerød 2620320, Region H 3400
    Denmark

    Active - Recruiting

  • Vejle sygehus

    Vejle 2610613, Region S 7100
    Denmark

    Active - Recruiting

  • Køge øre næse hals afd

    Køge 2618415, Region Sj 4600
    Denmark

    Active - Recruiting

  • Dept. of otorhinolaryngology, Odense

    Odense 2615876, Region Syd 5000
    Denmark

    Active - Recruiting

  • Gødstrup Hospital

    Gødstrup 2621315,
    Denmark

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.